CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue:
Royalty income	$ 2,380	$ 1,773	$ 4,569	$ 1,947
Collaboration revenue	6,073	145	6,315	210
Other revenues	23	19	42	28
Total revenue	8,476	1,937	10,926	2,185
Operating expenses:
Research and development	7,988	6,718	17,137	13,207
General and administrative	5,599	6,127	11,416	9,852
Change in contingent consideration liability	600	800	800	1,100
Total operating expenses	14,187	13,645	29,353	24,159
Operating loss	(5,711)	(11,708)	(18,427)	(21,974)
Other income:
Interest income	54	11	97	23
Total other income	54	11	97	23
Net loss	(5,657)	(11,697)	(18,330)	(21,951)
Net loss attributable to noncontrolling interests	(19)	0	(37)	0
Net loss attributable to Progenics	$ (5,638)	$ (11,697)	$ (18,293)	$ (21,951)
Net loss per share attributable to Progenics - basic and diluted (in dollars per share)	$ (0.08)	$ (0.17)	$ (0.26)	$ (0.32)
Weighted-average shares - basic and diluted (in shares)	69,947	69,647	69,947	69,642